Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOBERMANN: Low-dose dobutamine and single-dose tocilizumab in high-risk acute myocardial infarction
2024-515999-13-00Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dobutamine and tocilizumab in myocardial infarction (MI) and cardiogenic shock (4 arms), sponsored by Rigshospitalet. Primary endpoint: NTproBNP change from admission to 48 hours. Started Mar 2022; status: completed.
02
Drugs
dobutaminetocilizumab
03
Conditions
myocardial infarction (MI)cardiogenic shock
Beyond the preview
Go deeper on 2024-515999-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515999-13-00.